Antiviral Drug Cuts Cancer Risk in Hepatitis B (CME/CE)
BOSTON (MedPage Today) — For patients with chronic hepatitis B, long-term treatment with entecavir (Baraclude) significantly cut the risk of liver cancer, researchers reported.
Antiviral Drug Cuts Cancer Risk in Hepatitis B (CME/CE)
BOSTON (MedPage Today) — For patients with chronic hepatitis B, long-term treatment with entecavir (Baraclude) significantly cut the risk of liver cancer, researchers reported.
Antiviral Drug Cuts Cancer Risk in Hepatitis B (CME/CE)
BOSTON (MedPage Today) — For patients with chronic hepatitis B, long-term treatment with entecavir (Baraclude) significantly cut the risk of liver cancer, researchers reported.
Antiviral Drug Cuts Cancer Risk in Hepatitis B (CME/CE)
BOSTON (MedPage Today) — For patients with chronic hepatitis B, long-term treatment with entecavir (Baraclude) significantly cut the risk of liver cancer, researchers reported.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com